Patents-Review.com
🔗 Permalink
Inventor profile of:

Joseph Collard

City:

Delray Beach, Florida

Country:

United States

Published Applications:

133

Last publication date:

2022-06-23

Top Assignees for applications by Joseph Collard

The entities that hold a legal rights for patent applications filed by inventor Collard Joseph:

Recent patent applications by Collard Joseph

Joseph Collard from Delray Beach, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2022-06-23
US20220195439A1
Chemistry; metallurgy

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

 #2 | 2020-09-17
US20200291407A1
Chemistry; metallurgy

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

 #3 | 2020-04-30
US20200131517A1
Chemistry; metallurgy

Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)

 #4 | 2020-01-30
US20200032263A1
Chemistry; metallurgy

Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene

 #5 | 2019-10-10
US20190309303A1
Chemistry; metallurgy

Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene

 #6 | 2019-10-10
US20190309295A1
Chemistry; metallurgy

Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene

 #7 | 2019-02-07
US20190040394A1
Chemistry; metallurgy

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

 #8 | 2019-01-24
US20190024084A1
Chemistry; metallurgy

Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity

 #9 | 2018-10-25
US20180305693A1
Chemistry; metallurgy

Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene

 #10 | 2018-08-16
US20180230468A1
Chemistry; metallurgy

Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1

 #11 | 2018-07-26
US20180208930A1
Chemistry; metallurgy

TREATMENT OF LIPID TRANSPORT AND METABOLISM GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A LIPID TRANSPORT AND METABOLISM GENE

 #12 | 2018-07-26
US20180208929A1
Chemistry; metallurgy

Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor

 #13 | 2018-07-19
US20180201931A1
Chemistry; metallurgy

Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)

 #14 | 2018-05-17
US20180135050A1
Chemistry; metallurgy

Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA

 #15 | 2018-03-08
US20180066260A1
Chemistry; metallurgy

Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8

 #16 | 2018-02-22
US20180051286A1
Chemistry; metallurgy

Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1

 #17 | 2018-02-08
US20180037891A1
Chemistry; metallurgy

Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG

 #18 | 2018-01-11
US20180010131A1
Chemistry; metallurgy

Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO

 #19 | 2018-01-04
US20180002696A1
Chemistry; metallurgy

Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA

 #20 | 2017-12-14
US20170355996A1
Chemistry; metallurgy

Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1

 #21 | 2017-12-14
US20170355995A1
Chemistry; metallurgy

Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21

 #22 | 2017-12-14
US20170355990A1
Chemistry; metallurgy

TREATMENT OF SODIUM CHANNEL, VOLTAGE-GATED, ALPHA SUBUNIT (SCNA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SCNA

 #23 | 2017-11-16
US20170327828A1
Chemistry; metallurgy

Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4

 #24 | 2017-08-10
US20170226516A1
Chemistry; metallurgy

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

 #25 | 2017-06-01
US20170152515A1
Chemistry; metallurgy

Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1

 #26 | 2017-05-25
US20170145414A1
Chemistry; metallurgy

Treatment of Frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN

 #27 | 2017-05-25
US20170145411A1
Chemistry; metallurgy

Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2

 #28 | 2017-03-16
US20170073680A1
Chemistry; metallurgy

Treatment of Collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene

 #29 | 2016-11-24
US20160340678A1
Chemistry; metallurgy

Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF

 #30 | 2016-10-06
US20160289759A1
Chemistry; metallurgy

Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related disease by inhibition of natural antisense transcript to PYCR1

 #31 | 2016-09-29
US20160281088A1
Chemistry; metallurgy

Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG

 #32 | 2016-09-22
US20160273037A1
Chemistry; metallurgy

Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisene transcript to CSF3

 #33 | 2016-06-16
US20160168574A1
Chemistry; metallurgy

TREATMENT OF INSULIN GENE (INS) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO AN INSULIN GENE (INS)

 #34 | 2016-06-16
US20160168568A1
Chemistry; metallurgy

Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ)

 #35 | 2016-05-19
US20160138023A1
Chemistry; metallurgy

Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF

 #36 | 2016-05-12
US20160130584A1
Chemistry; metallurgy

Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA

 #37 | 2016-03-31
US20160090599A1
Chemistry; metallurgy

Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1

 #38 | 2016-02-18
US20160046942A1
Chemistry; metallurgy

Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG

 #39 | 2016-01-28
US20160024506A1
Chemistry; metallurgy

Treatment of LCAT gene related diseases by inhibition of a natural antisense transcript to LCAT

 #40 | 2016-01-28
US20160024505A1
Chemistry; metallurgy

Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene

 #41 | 2016-01-14
US20160010092A1
Chemistry; metallurgy

Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP

 #42 | 2016-01-07
US20160002640A1
Chemistry; metallurgy

Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1

 #43 | 2015-12-24
US20150368644A1
Chemistry; metallurgy

TREATMENT OF INTERFERON-RELATED DEVELOPMENTAL REGULATOR 1 (IFRD1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IFRD1

 #44 | 2015-11-26
US20150337307A1
Chemistry; metallurgy

Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene

 #45 | 2015-10-22
US20150299701A1
Chemistry; metallurgy

Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor

 #46 | 2015-10-08
US20150284724A1
Chemistry; metallurgy

Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)

 #47 | 2015-09-24
US20150267204A1
Chemistry; metallurgy

Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)

 #48 | 2015-09-17
US20150259685A1
Chemistry; metallurgy

Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2

 #49 | 2015-08-20
US20150232850A1
Chemistry; metallurgy

Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3)

 #50 | 2015-08-13
US20150225725A1
Chemistry; metallurgy

Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21

 #51 | 2015-08-13
US20150225724A1
Chemistry; metallurgy

Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)

 #52 | 2015-07-16
US20150197750A1
Chemistry; metallurgy

Treatment of ‘IQ motif containing gtpase activating protein’ (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP

 #53 | 2015-06-18
US20150167007A1
Chemistry; metallurgy

TREATMENT OF SIALIDASE 4 (NEU4) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO NEU4

 #54 | 2015-06-18
US20150166994A1
Chemistry; metallurgy

Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG

 #55 | 2015-06-11
US20150159162A1
Chemistry; metallurgy

Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene

 #56 | 2015-06-04
US20150152426A1
Chemistry; metallurgy

Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4

 #57 | 2015-06-04
US20150152425A1
Chemistry; metallurgy

Treatment of Methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA

 #58 | 2015-06-04
US20150152424A1
Chemistry; metallurgy

Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1

 #59 | 2015-06-04
US20150152419A1
Chemistry; metallurgy

Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3

 #60 | 2015-06-04
US20150152417A1
Chemistry; metallurgy

Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity

 #61 | 2015-05-21
US20150141494A1
Chemistry; metallurgy

Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF

 #62 | 2015-05-14
US20150133526A1
Chemistry; metallurgy

Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG

 #63 | 2015-05-14
US20150133525A1
Chemistry; metallurgy

Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1

 #64 | 2015-05-07
US20150126587A1
Chemistry; metallurgy

Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63

 #65 | 2015-04-30
US20150119451A1
Chemistry; metallurgy

Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8

 #66 | 2015-04-16
US20150105451A1
Chemistry; metallurgy

Treatment of Paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1

 #67 | 2015-04-02
US20150094358A1
Chemistry; metallurgy

Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF

 #68 | 2015-04-02
US20150094356A1
Chemistry; metallurgy

Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family

 #69 | 2015-03-26
US20150087695A1
Chemistry; metallurgy

Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO

 #70 | 2015-03-19
US20150080456A1
Chemistry; metallurgy

Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1

 #71 | 2015-03-19
US20150080455A1
Chemistry; metallurgy

Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to TFE3

 #72 | 2015-03-12
US20150073040A1
Chemistry; metallurgy

Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene

 #73 | 2015-02-26
US20150057338A1
Chemistry; metallurgy

Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene

 #74 | 2015-02-05
US20150038553A1
Chemistry; metallurgy

Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1

 #75 | 2014-12-18
US20140371301A1
Chemistry; metallurgy

Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2

 #76 | 2014-10-16
US20140309181A1
Human necessities

Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules

 #77 | 2014-09-25
US20140288153A1
Chemistry; metallurgy

Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene

 #78 | 2014-09-25
US20140288152A1
Chemistry; metallurgy

Treatment of ‘C terminus of HSP7O-interacting protein’ (CHIP) related diseases by inhibition of natural antisense transcript to CHIP

 #79 | 2014-07-03
US20140187606A1
Chemistry; metallurgy

Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN

 #80 | 2014-06-05
US20140155464A1
Chemistry; metallurgy

Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP

 #81 | 2013-10-03
US20130261065A1
Chemistry; metallurgy

Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG

 #82 | 2013-09-26
US20130253036A1
Chemistry; metallurgy

Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA

 #83 | 2013-09-19
US20130245099A1
Chemistry; metallurgy

Antagonat compositions and methods of use

 #84 | 2013-09-19
US20130245095A1
Chemistry; metallurgy

Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4

 #85 | 2013-08-15
US20130210893A1
Chemistry; metallurgy

TREATMENT OF INTERFERON-RELATED DEVELOPMENTAL REGULATOR 1 (IFRD1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IFRD1

 #86 | 2013-07-18
US20130184325A9
Chemistry; metallurgy

TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO HGF

 #87 | 2013-06-06
US20130143946A1
Human necessities

Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG

 #88 | 2013-05-30
US20130137751A1
Chemistry; metallurgy

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

 #89 | 2013-05-09
US20130116300A1
Human necessities

Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1

 #90 | 2013-04-18
US20130096183A1
Chemistry; metallurgy

Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA

 #91 | 2013-04-04
US20130085112A1
Chemistry; metallurgy

Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1

 #92 | 2013-03-21
US20130072546A1
Chemistry; metallurgy

Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA

 #93 | 2013-03-21
US20130072421A1
Chemistry; metallurgy

Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)

 #94 | 2013-03-14
US20130065947A1
Chemistry; metallurgy

Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4

 #95 | 2013-02-07
US20130035373A1
Chemistry; metallurgy

Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21

 #96 | 2013-02-07
US20130035372A1
Chemistry; metallurgy

Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3

 #97 | 2012-12-27
US20120329855A1
Chemistry; metallurgy

Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF

 #98 | 2012-12-27
US20120329727A1
Chemistry; metallurgy

Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2

 #99 | 2012-12-20
US20120322853A1
Chemistry; metallurgy

Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene

 #100 | 2012-12-06
US20120309814A1
Chemistry; metallurgy

Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
InventorID:

80087 ⎘